Although studies have demonstrated the efficacy of the new anti-epileptic on the block, Pregabalin, in the treatment of Generalized Anxiety Disorder and Social Anxiety Disorder, there is no study so far of such efficacy for the treatment of depression.

This case study in a patient with chronic major depression demonstrates that Pregabalin could be an effective augmenting agent to other anti-depressants, e.g. SSRI’s and SNRI’s.

This added property of Pregabalin may be related to its probable GABA-ergic mechanism of action that could be soon the emerging treatment pathway for achieving better remission in chronic depression that is yet clinically problematic.

Key Words: Pregabalin • depression • augmentation • anxiety • GABA

Mostafa Showraki
Community Psychiatrists Association of Toronto, Ontario, Canada, .(JavaScript must be enabled to view this email address)

Journal of Psychopharmacology, Vol. 21, No. 8, 883-884 (2007)
DOI: 10.1177/0269881107078496
British Association for Psychopharmacology